Research programme: therapeutic antibodies - Epitomics/InNexus
Latest Information Update: 02 Dec 2010
At a glance
- Originator Epitomics; InNexus Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action Apoptosis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Myocardial infarction; Stroke
Most Recent Events
- 22 Mar 2006 DXL™ Technology is available for licensing or partnering worldwide (http://www.innexusbiotech.com)
- 12 Jan 2005 Preclinical trials in Myocardial infarction in USA (unspecified route)
- 12 Jan 2005 Preclinical trials in Stroke in USA (unspecified route)